Presentation is loading. Please wait.

Presentation is loading. Please wait.

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,

Published byMarie-Josèphe Denis Modified over 5 years ago

Similar presentations

Presentation on theme: "Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,"— Presentation transcript:

1 Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD, PhD, Craig Leonardi, MD, Kim A. Papp, MD, PhD, FRCPC, Ulrich Mrowietz, MD, Mamitaro Ohtsuki, MD, PhD, Robert Bissonnette, MD, MSc, FRCPC, Laura K. Ferris, MD, PhD, Carle Paul, MD, PhD, Mark Lebwohl, MD, FAAD, Daniel K. Braun, MD, PhD, Lotus Mallbris, MD, PhD, Stefan Wilhelm, MD, Wen Xu, PhD, Anders Ljungberg, MD, Nayan Acharya, MBBS, MRCP, MFPM, Kristian Reich, MD, PhD  Journal of the American Academy of Dermatology  Volume 76, Issue 3, Pages e17 (March 2017) DOI: /j.jaad Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Psoriasis. Drug exposure. The number of patients exposed to ixekizumab. In the Psoriasis Placebo- and Active-Controlled Integrated Analysis Set, the median exposure times were 85.0 days (maximum 197) for ixekizumab every 4 weeks (Q4W) and 85.0 days (maximum 116) for ixekizumab every 2 weeks (Q2W). The median exposure time for patients in the Psoriasis Maintenance Integrated Analysis Set treated with ixekizumab Q2W induction dosing/Q4W maintenance dosing was (maximum 370) and with ixekizumab Q4W/Q4W was 337.0 days (maximum 434). Journal of the American Academy of Dermatology  , e17DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Psoriasis. Adverse events (AEs) of special interest. Exposure-adjusted incidence rates (IRs)/100 patient-years (PY). The exposure-adjusted IRs for treatment-emergent AEs represent the number of patients with a particular event/100 PY of exposure. Time during the treatment period was considered entire exposure time. The symbol is the exposure-adjusted IR and the bars are 95% confidence intervals. During the induction period, the IRs are from the Psoriasis Placebo (PBO)- and Active-Controlled Integrated Analysis Set. A, Serious infections. B, Candida (high-level terms [HLTs] and clinical terms). C, Oral Candida (HLTs and clinical terms). D, Nonmelanoma skin cancers (NMSC). E, Malignancies excluding NMSC. F, Crohn's disease. G, Ulcerative colitis. H, Major adverse cardiovascular events (MACE); total PY is for MACE because adjudication was only performed for the phase (Ph) III trials. I, Injection-site reactions (composite of injection site reaction–related terms). ETN, Etanercept; IXE, ixekizumab 80 mg; LTE, long-term extension; Ps, psoriasis; Q2W, every 2 weeks; Q4W, every 4 weeks; Q12W, every 12 weeks; RCT, randomized-controlled trial; WD, withdrawal. Journal of the American Academy of Dermatology  , e17DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Alexander Egeberg, MD, PhD, Lone Skov, MD, PhD, DMSc, Aditya A

Alexander Egeberg, MD, PhD, Lone Skov, MD, PhD, DMSc, Aditya A
Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus  Akiko Kishi, MD, Nobukazu Hayashi, MD, PhD,

Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus  Akiko Kishi, MD, Nobukazu Hayashi, MD, PhD,
Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
A girl with a solitary red bulla

A girl with a solitary red bulla
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Psoriasis is associated with lipid abnormalities at the onset of skin disease  Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,

Psoriasis is associated with lipid abnormalities at the onset of skin disease  Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case- control study from Denmark  Sidsel Arnspang Pedersen, MD, David Gaist,

Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case- control study from Denmark  Sidsel Arnspang Pedersen, MD, David Gaist,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort  Shelley.

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort  Shelley.
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Similar presentations

Ads by Google